Pharmacist Moms Group^™

Jessica Lewis-Gonzalez, PharmD, BCOP, discusses the management of hematologic and non-hematologic toxicities in cancer patients, emphasizing the importance of proactive monitoring and collaboration between clinicians and pharmacists.

Michael Fifer, MD, discusses the Maple HCM study, which compared the cardiac myosin inhibitor Aficamten and the beta blocker Metoprolol in patients with obstructive hypertrophic cardiomyopathy (HCM).

ChatGPT said: Crystal Hodge, PharmD, BCIDP, BCPS, emphasized that declining vaccination rates below the 95% herd immunity threshold have fueled recent measles outbreaks, underscoring the urgent need for pharmacist-led vaccination advocacy.

Legislative efforts aim to improve oncology medication access, addressing transportation barriers and advocating for mail delivery from cancer clinics.

Elizabeth Vaughan, MD, MPH, RD, highlights how pharmacists can build patient trust, encourage vaccination, and use simple strategies to spark conversations with hesitant individuals.

An expert emphasizes the importance of prompt antiviral treatment and personalized pain management for shingles—particularly in high-risk patients—while highlighting the pharmacist’s role in guiding appropriate over-the-counter care, promoting vaccination through timely conversations, and leveraging tools like immunization registries and word of mouth to improve prevention efforts.

An expert highlights the critical role of vaccination in preventing shingles—especially for high-risk patients with chronic conditions—while addressing challenges like postpandemic vaccine fatigue, emphasizing pharmacists’ unique position to build trust, offer timely education during routine visits, and improve uptake through personalized, visually supported, and seasonally timed conversations.

Joshua K. Sabari, MD, highlights pharmacists’ roles in coordinating access, financial assistance, and early side effect management for patients starting zongertinib (Hernexeos).

Joshua K. Sabari, MD, explains zongertinib’s (Hernexeos) favorable safety profile and quality-of-life benefits over intravenous antibody-drug conjugates in patients with HER2-mutated non-small cell lung cancer (NSCLC).